In re Under Armour Securities Litigation

District Court, D. Maryland·Decided April 16, 2024·No. 1:17-cv-00388·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

* IN RE UNDER ARMOUR SECURITIES LITIGATION * Civil Action No. RDB-17-0388

*

* * * * * * * * * * * * * MEMORANDUM OPINION The instant securities class action against Defendants Under Armour, Inc. (“Under Armour”) and Kevin Plank (“Plank”) (collectively, “Defendants”) has been ongoing since February 10, 2017. (ECF No. 1.) A twelve-day jury trial is scheduled to begin on July 15, 2024. (ECF No. 295.) This matter comes before the Court on the three (3) motions to exclude expert testimony and opinions filed by Plaintiffs (ECF Nos. 302, 305, 308), and four (4) motions to exclude expert testimony and opinions filed by Defendants (ECF Nos. 309, 311, 314, 316) (collectively with ECF Nos. 302, 305, 308, the “Daubert Motions”). The Court heard oral argument on the Daubert Motions on April 9, 2024. (ECF No. 387.) As the seven pending Daubert Motions (ECF Nos. 302, 305, 308, 309, 311, 314, 316) are all DENIED by separate Order, this Memorandum Opinion expounds upon the Court’s reasoning. BACKGROUND This securities class action is scheduled for a twelve-day trial beginning on July 15, 2024. (ECF No. 295.) The parties’ Daubert Motions concern the parties’ disagreement as to whether one of the proposed experts may testify at all1 and whether certain of the proposed experts’ testimony and opinions should be limited. Specifically, Defendants move to exclude entirely testimony and opinions of Mark A. Cohen (“Cohen”), Plaintiffs’ proffered

experiential expert on the retail and apparel industry, (ECF No. 314); and Plaintiffs move to exclude certain testimony of Defendant Under Armour’s proffered rebuttal expert to Cohen, Laurie Wilson (“Wilson”), (ECF No. 308). Defendants seek to limit the testimony and opinions of Professor M. Todd Henderson (“Henderson”), Plaintiffs’ proffered expert on Plank’s trading of Under Armour stock and Plank’s Rule 10b5-1 trading plan, (ECF No. 309); and Plaintiffs seek to limit the testimony and opinions of Defendant Plank’s proffered rebuttal

expert to Henderson, Wayne Guay (“Guay”), (ECF No. 305). Defendants have also moved to limit the testimony and opinions of Plaintiffs’ proffered accounting expert D. Paul Regan (“Regan”). (ECF No. 11.) Lastly, Defendants seek to limit the testimony and opinions of Dr. Matthew Cain, Ph.D. (“Cain”), Plaintiffs’ proffered market efficiency, materiality, loss causation, and damages expert, (ECF No. 316); and Plaintiffs seek to limit the testimony and opinions of Defendant Under Armour’s proffered rebuttal expert to Cain, Paul A. Gompers

(“Gompers”), (ECF No. 302). STANDARD OF REVIEW Pursuant to Rule 104(a) of the Federal Rules of Evidence, courts are responsible for determining “preliminary questions concerning the qualifications of a person to be a witness”

1 While Defendants’ written submissions requested to exclude entirely the testimony and opinions of Professor M. Todd Henderson (ECF No. 309) and Matthew D. Cain, Ph.D. (ECF No. 316), Defendants clarified on the record at the April 9, 2024 hearing that they only sought to limit Henderson and Cain’s testimony. Similarly, while Plaintiffs’ written submissions requested to exclude Laurie Wilson entirely (ECF No. 308), Plaintiffs clarified on the record at the April 9, 2024 hearing that they only sought to limit Wilson’s testimony. and “the admissibility of evidence.” This includes the admissibility of expert testimony under Rule 702, which provides: A witness who is qualified as an expert by knowledge, skill, experience, training, or education may testify in the form of an opinion or otherwise if: (a) the expert’s scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue; (b) the testimony is based on sufficient facts or data; (c) the testimony is the product of reliable principles and methods; and (d) the expert has reliably applied the principles and methods to the facts of the case. FED. R. EVID. 702. Pursuant to Rule 702, a properly qualified expert witness may testify regarding technical, scientific, or other specialized knowledge in a given field if the testimony would assist the trier of fact in understanding the evidence or to determine a fact in issue, and the testimony is both reliable2 and relevant.3 United States v. Young, 916 F.3d 368, 379 (4th Cir. 2019). The proponent of the expert testimony in question must establish admissibility by a preponderance of the evidence. Cooper v. Smith & Nephew, Inc., 259 F.3d 194, 199 (4th Cir. 2001) (citing Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 589, 592 n.10 (1993)). A court’s role in applying Rule 702 is to act as a gatekeeper, ensuring that expert testimony is relevant and reliable. Daubert, 509 U.S. at 592–93; see also Kumho Tire Co. v. Carmichael, 526 U.S. 137, 141 (1999) (holding that Daubert’s gatekeeping obligation applies not only to scientific testimony but to all expert testimony); Bresler v. Wilmington Tr. Co., 855 F.3d

2 To be reliable, testimony must be grounded “in the methods and procedures of science,” and it must be something more than subjective belief or unsupported assumptions. Daubert, 509 U.S. at 589–90. 3 Evidence or testimony must be relevant to the extent that it will “assist the trier of fact to understand the evidence or to determine a fact in issue.” Daubert, 509 U.S. at 591. An expert’s testimony is relevant if it has “‘a valid scientific connection to the pertinent inquiry.’” Belville v. Ford Motor Co., 919 F.3d 224, 232 (4th Cir. 2019) (citation omitted). 178, 195 (4th Cir. 2017) (“Under Rule 702 . . . [c]ourts are required to act as ‘gatekeepers’ to ensure that expert testimony is relevant and reliable.” (quoting Cooper, 259 F.3d at 199)). However, the Supreme Court did not intend the gatekeeper role to replace the adversary

system or the role of the jury: “[v]igorous cross-examination, presentation of contrary evidence, and careful instruction on the burden of proof are the traditional and appropriate means of attacking shaky but admissible evidence.” Daubert, 509 U.S. at 596; see United States v. Moreland, 437 F. 3d 424, 431 (4th Cir. 2006) (recognizing that “expert testimony is subject to testing by vigorous cross-examination, presentation of contrary evidence, and careful instruction on the burden of proof”). “[C]onsequently, the rejection of expert testimony is

the exception rather than the rule.” Lipitor (Atorvastatin Calcium) Mktg. v. Pfizer, Inc., 892 F.3d 624, 631 (4th Cir. 2018) (quoting United States v. Stanley, 533 F. App’x 325, 327 (4th Cir. 2013)). Although Rule 702 allows for a liberal introduction of expert evidence, “courts must recognize that due to the difficulty of evaluating their testimony, expert witnesses have the potential to ‘be both powerful and quite misleading.’” Westberry v. Gislaved Gummi AB, 178 F.3d 257, 261 (4th Cir. 1999) (quoting Daubert, 509 U.S. at 595). In Daubert v. Merrell Dow

Pharmaceuticals, Inc., 509 U.S. 579

Free access — add to your briefcase to read the full text and ask questions with AI

In re Under Armour Securities Litigation, (D. Md. 2024).

In re Under Armour Securities Litigation (In re Under Armour Securities Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
United States v. Paul Stanley
533 F. App'x 325 (Fourth Circuit, 2013)
In Re Executive Telecard, Ltd. Securities Litigation
979 F. Supp. 1021 (S.D. New York, 1997)
In Re Apollo Group Inc. Securities Litigation
509 F. Supp. 2d 837 (D. Arizona, 2007)
Cooper v. Smith & Nephew, Inc.
259 F.3d 194 (Fourth Circuit, 2001)
In re Vivendi, S.A. Secs. Litig.
838 F.3d 223 (Second Circuit, 2016)
United States v. Jarelle McLean
695 F. App'x 681 (Fourth Circuit, 2017)
Phillip J. Singer v. Kenneth Reali
883 F.3d 425 (Fourth Circuit, 2018)
Lipitor (Atorvastatin Calcium) Mktg. v. Pfizer, Inc.
892 F.3d 624 (Fourth Circuit, 2018)
United States v. Nicholas Young
916 F.3d 368 (Fourth Circuit, 2019)
Lance Belville v. Ford Motor Company
919 F.3d 224 (Fourth Circuit, 2019)
Westberry v. Gislaved Gummi AB
178 F.3d 257 (Fourth Circuit, 1999)
Miller v. Asensio & Co.
364 F.3d 223 (Fourth Circuit, 2004)